The company's pipeline of targeted pro-drugs can release chemotherapy drugs inside cancer cells, reducing the systemic toxicity associated with conventional chemotherapy treatments. BioSight's novel peptide-based drugs target and release therapeutic enzymes inside cancer cells, providing safe and effective treatment for haematological malignancies and disorders.